Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Biodesix (NASDAQ: BDSX) and Bio-Rad Laboratories have contributed to groundbreaking research findings from Friends of Cancer Research's ctMoniTR Project, published in Clinical Cancer Research. The study demonstrates a strong correlation between circulating tumor DNA (ctDNA) changes and treatment outcomes in cancer patients.
The research expands on previous findings, analyzing multiple solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. The study utilized Bio-Rad's Droplet Digital™ PCR technology to detect ctDNA from patient samples.
Biodesix is currently exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD), with latest advancements to be presented at the upcoming American Association for Cancer Research Annual Meeting on April 28th, 2025.
Biodesix (NASDAQ: BDSX) e Bio-Rad Laboratories hanno contribuito a risultati di ricerca innovativi dal progetto ctMoniTR di Friends of Cancer Research, pubblicati su Clinical Cancer Research. Lo studio dimostra una forte correlazione tra le variazioni del DNA tumorale circolante (ctDNA) e gli esiti del trattamento nei pazienti oncologici.
La ricerca amplia i risultati precedenti, analizzando diversi tipi di tumori solidi e categorie di trattamento, inclusi pazienti trattati con inibitori delle tirosin-chinasi. Lo studio ha utilizzato la tecnologia Droplet Digital™ PCR di Bio-Rad per rilevare il ctDNA dai campioni dei pazienti.
Biodesix sta attualmente esplorando l’uso combinato del ctDNA e della proteomica per individuare la malattia residua molecolare (MRD), con le ultime novità che saranno presentate al prossimo Annual Meeting dell’American Association for Cancer Research il 28 aprile 2025.
Biodesix (NASDAQ: BDSX) y Bio-Rad Laboratories han contribuido a hallazgos innovadores del proyecto ctMoniTR de Friends of Cancer Research, publicados en Clinical Cancer Research. El estudio demuestra una fuerte correlación entre los cambios en el ADN tumoral circulante (ctDNA) y los resultados del tratamiento en pacientes con cáncer.
La investigación amplía hallazgos previos, analizando múltiples tipos de tumores sólidos y categorías de tratamiento, incluyendo pacientes tratados con inhibidores de tirosina quinasa. El estudio utilizó la tecnología Droplet Digital™ PCR de Bio-Rad para detectar el ctDNA en muestras de pacientes.
Actualmente, Biodesix está explorando la combinación de ctDNA con proteómica para detectar la enfermedad residual molecular (MRD), con los últimos avances que se presentarán en la próxima Reunión Anual de la American Association for Cancer Research el 28 de abril de 2025.
Biodesix (NASDAQ: BDSX)와 Bio-Rad Laboratories는 Friends of Cancer Research의 ctMoniTR 프로젝트에서 획기적인 연구 결과에 기여했으며, 해당 연구는 Clinical Cancer Research에 게재되었습니다. 이 연구는 순환 종양 DNA(ctDNA) 변화와 암 환자의 치료 결과 간 강한 상관관계를 보여줍니다.
이번 연구는 이전 결과를 확장하여 다양한 고형종양 유형과 치료 범주를 분석했으며, 티로신 키나제 억제제로 치료받은 환자도 포함되었습니다. 연구에는 Bio-Rad의 Droplet Digital™ PCR 기술이 환자 샘플에서 ctDNA를 검출하는 데 사용되었습니다.
Biodesix는 현재 ctDNA와 프로테오믹스를 결합하여 분자 잔류 질환(MRD)을 탐지하는 연구를 진행 중이며, 최신 연구 성과는 2025년 4월 28일에 열리는 미국 암 연구 협회 연례 회의에서 발표될 예정입니다.
Biodesix (NASDAQ : BDSX) et Bio-Rad Laboratories ont contribué à des découvertes majeures issues du projet ctMoniTR de Friends of Cancer Research, publiées dans Clinical Cancer Research. L’étude démontre une forte corrélation entre les variations de l’ADN tumoral circulant (ctDNA) et les résultats des traitements chez les patients atteints de cancer.
Cette recherche étend les résultats précédents en analysant plusieurs types de tumeurs solides et catégories de traitements, y compris des patients traités par inhibiteurs de tyrosine kinase. L’étude a utilisé la technologie Droplet Digital™ PCR de Bio-Rad pour détecter le ctDNA à partir des échantillons des patients.
Biodesix explore actuellement la combinaison du ctDNA avec la protéomique pour détecter la maladie résiduelle moléculaire (MRD), avec les dernières avancées qui seront présentées lors de la prochaine réunion annuelle de l’American Association for Cancer Research le 28 avril 2025.
Biodesix (NASDAQ: BDSX) und Bio-Rad Laboratories haben zu bahnbrechenden Forschungsergebnissen des ctMoniTR-Projekts von Friends of Cancer Research beigetragen, die in Clinical Cancer Research veröffentlicht wurden. Die Studie zeigt eine starke Korrelation zwischen Veränderungen des zirkulierenden Tumor-DNA (ctDNA) und den Behandlungsergebnissen bei Krebspatienten.
Die Forschung baut auf früheren Erkenntnissen auf und analysiert verschiedene solide Tumorarten und Behandlungskategorien, einschließlich Patienten, die mit Tyrosinkinase-Inhibitoren behandelt wurden. Für die Studie wurde die Droplet Digital™ PCR-Technologie von Bio-Rad verwendet, um ctDNA aus Patientenproben nachzuweisen.
Biodesix untersucht derzeit die Kombination von ctDNA mit Proteomik zur Erkennung molekularer Restkrankheit (MRD). Die neuesten Fortschritte werden auf der bevorstehenden Jahrestagung der American Association for Cancer Research am 28. April 2025 vorgestellt.
- Research validates ctDNA testing technology for cancer treatment monitoring
- Expansion of study scope to multiple tumor types strengthens clinical evidence
- Strategic partnership with Friends of Cancer Research enhances market position
- None.
Insights
Biodesix's ctDNA research validation broadens cancer monitoring applications, strengthening their diagnostic portfolio without immediate revenue impact.
This peer-reviewed publication in Clinical Cancer Research validates Biodesix's ctDNA testing approach through the multi-stakeholder ctMoniTR Project. The research demonstrates a strong association between ctDNA changes and treatment outcomes across multiple solid tumor types, expanding beyond previous findings to advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. The new research now includes patients treated with tyrosine kinase inhibitors, widening potential applications.
The significance here is two-fold: first, it shows Biodesix's technology can effectively detect these clinically relevant biomarkers using Bio-Rad's Droplet Digital PCR platform; second, it supports potential integration of ctDNA analysis in both therapeutic development programs and clinical care pathways. This aligns perfectly with Biodesix's existing service offerings, as they already provide ctDNA testing as part of their Development Services portfolio.
Notably, Biodesix is exploring combining ctDNA with proteomics for molecular residual disease (MRD) detection - an approach that addresses the critical challenge of identifying remaining cancer cells after treatment. This strategic direction targets a growing segment of cancer diagnostics focused on treatment monitoring and recurrence detection.
While this research strengthens Biodesix's scientific credibility in liquid biopsy diagnostics, the publication represents validation of existing approaches rather than announcing new products or commercial milestones.
Research expands ctDNA monitoring applications to more cancer types and treatments, validating Biodesix's approach without immediate clinical implementation.
This research significantly broadens the potential clinical utility of circulating tumor DNA (ctDNA) monitoring beyond the previously established applications in advanced non-small cell lung cancer. By expanding to additional solid tumor types and patients treated with tyrosine kinase inhibitors, the study demonstrates the versatility of this liquid biopsy approach across different cancer contexts.
The consistent finding of a strong association between ctDNA changes and overall survival addresses a major clinical challenge in oncology - the need for earlier treatment response assessment. Current standard-of-care relies heavily on imaging studies that typically require months to determine efficacy, potentially delaying crucial treatment modifications.
From a drug development perspective, this validation could support using ctDNA as an early efficacy biomarker in clinical trials, potentially accelerating therapeutic development timelines. The collaboration's breadth - involving industry, government, academia, and advocacy groups through Friends of Cancer Research - lends substantial credibility to these findings.
Biodesix's exploration of combining ctDNA with proteomics for molecular residual disease detection represents a sophisticated approach to post-treatment monitoring. This technique could potentially offer greater sensitivity than either approach alone for detecting minimal remaining disease.
While scientifically significant, the research doesn't specify timelines for clinical implementation or regulatory pathways, representing ongoing scientific progress rather than immediate clinical practice change.
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology
LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care.
The ctMoniTR Project (ctDNA to Monitor Treatment Response) was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients. Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors.
Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital™ PCR (ddPCR™) * technology to detect ctDNA from patient samples.
“Biodesix is proud to be a partner on this important project, which has the potential to support a transformation of therapeutic development and clinical cancer care,” said Gary Pestano, PhD, Chief Development Officer at Biodesix. “The ctMoniTR Project is aligned with the mission and vision of Biodesix Development Services, as we strive to challenge the science and solutions of today, in order to evolve and adapt clinical decision-making to improve patient care and outcomes.”
“We are very pleased that Droplet Digital™ PCR (ddPCR™) was selected for use within this study,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. “These collaborations and research programs are vital as we work towards establishing novel methods for molecular residual disease monitoring in oncology, supporting the advancement of scientific research and ultimately healthcare.”
Beyond this specific research project, Biodesix offers ctDNA testing, using ddPCR technology, as part of its Development Services portfolio and is also exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD). The latest advancements in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 28th, 2025.
*Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.
Media Contacts:
Biodesix, Inc.
Natalie St. Denis, Director Corporate Communications
+1 720-925-9285
Natalie.stdenis@biodesix.com
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications (Bio-Rad PR firm)
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, click here.
About Biodesix
Biodesix, Inc. (Nasdaq: BDSX) is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics across disease states. For more information, visit biodesix.com.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in both Biodesix and Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q. Biodesix and Bio-Rad caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
FAQ
What are the key findings of the ctMoniTR Project involving Biodesix (BDSX)?
How is Biodesix (BDSX) utilizing ctDNA technology in cancer treatment?
What will Biodesix (BDSX) present at the AACR Annual Meeting in April 2025?
What types of cancer patients were included in the Biodesix (BDSX) ctMoniTR study?
